Martek patent fight
This article was originally published in The Tan Sheet
Executive Summary
Columbia, Md. firm's European patent for its docosahexaenoic acid (DHA) and arachidonic acid (ARA) oil blends is revoked in Munich, Germany court proceeding, Martek announces Nov. 12. The firm says it will file an appeal within a matter of days that will automatically reinstate the patent; Martek expects the appeal process to exceed two years. Management believes the patent issue will not impact infant formula sales in the short-term, but could lead to greater competition and decreased sales in Europe if the firm ultimately loses the appeal...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.